Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 13, 2020 - Issue
Submit an article Journal homepage
147
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function

Ian D Pavord1 Respiratory Medicine Unit and Oxford Respiratory National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4288-5973View further author information
ORCID Icon,
Salman Siddiqui2 University of Leicester and Leicester National Institute for Health Research Biomedical Research Centre (Respiratory Theme), Leicester, UKView further author information
,
Alberto Papi3 Department of Respiratory Medicine, University of Ferrara, Ferrara, ItalyORCID Iconhttps://orcid.org/0000-0002-6924-4500View further author information
ORCID Icon,
Jonathan Corren4 David Geffen School of Medicine at UCLA, Los Angeles, CA, USAView further author information
,
Lawrence D Sher5 Peninsula Research Associates, Rolling Hills Estate, CA, USAView further author information
,
Philip Bardin6 Department of Lung and Sleep Medicine, Monash University and Medical Centre, Clayton, Melbourne, VIC, AustraliaView further author information
,
David Langton7 Department of Thoracic Medicine, Frankston Hospital, Frankston, Melbourne, VIC, AustraliaView further author information
,
Hae-Sim Park8 Ajou University Hospital, Suwon, South KoreaORCID Iconhttps://orcid.org/0000-0003-2614-0303View further author information
ORCID Icon,
Megan S Rice9 Sanofi, Cambridge, MA, USAView further author information
,
Yamo Deniz10 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USAView further author information
,
Paul Rowe11 Sanofi, Bridgewater, NJ, USAView further author information
,
Heribert W Staudinger11 Sanofi, Bridgewater, NJ, USAView further author information
,
Naimish Patel11 Sanofi, Bridgewater, NJ, USAView further author information
,
Marcella Ruddy10 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USAView further author information
,
Neil M H Graham10 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USAView further author information
&
Ariel Teper11 Sanofi, Bridgewater, NJ, USAView further author information
 show all
Pages 701-711 | Published online: 16 Dec 2020

References

  • Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention; 2018 Available from: https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-tracked_v1.3.pdf. Accessed 84, 2020.
  • Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071. doi:10.1164/rccm.200701-085OC17872493
  • Kips JC, O’Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti–human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167(12):1655–1659. doi:10.1164/rccm.200206-525OC12649124
  • Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811. doi:10.1164/rccm.201208-1414OC23471469
  • MacDonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci. 2014;111(14):5147–5152. doi:10.1073/pnas.132389611124706858
  • Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111(14):5153–5158. doi:10.1073/pnas.132402211124706856
  • Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204. doi:10.1111/all.1415131838750
  • Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi:10.1080/1744666X.2017.129844328277826
  • DUPIXENT ® (dupilumab). Highlights of prescribing information. US Food and Drug Administration; 2019 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf. Accessed 84, 2020.
  • DUPIXENT ® (dupilumab). Summary of product characteristics. European Medicines Agency; 2017 Available from: http://ec.europa.eu/health/documents/community-register/2019/20190506144541/anx_144541_en.pdf. Accessed 84, 2020.
  • Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa180409229782217
  • Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553–558. doi:10.1016/j.rmed.2004.10.00815823451
  • Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47(1):81–87. doi:10.1016/0895-4356(94)90036-18283197
  • Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi:10.1016/S2213-2600(15)00042-925736990
  • Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa180409329782224
  • Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44. doi:10.1016/S0140-6736(16)30307-527130691
  • Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15:35–50. doi:10.1038/nrd462426471366
  • Locksley RM. Asthma and allergic inflammation. Cell. 2010;140(6):777–783. doi:10.1016/j.cell.2010.03.00420303868

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.